Swiss National Bank Buys 30,100 Shares of Sotera Health (NASDAQ:SHC)

Swiss National Bank increased its stake in shares of Sotera Health (NASDAQ:SHC - Free Report) by 10.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 306,400 shares of the company's stock after buying an additional 30,100 shares during the period. Swiss National Bank owned 0.11% of Sotera Health worth $4,192,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Darsana Capital Partners LP lifted its holdings in shares of Sotera Health by 716.9% during the 3rd quarter. Darsana Capital Partners LP now owns 20,010,000 shares of the company's stock worth $334,167,000 after acquiring an additional 17,560,636 shares during the period. State Street Corp increased its holdings in Sotera Health by 18.5% in the third quarter. State Street Corp now owns 4,126,806 shares of the company's stock valued at $68,918,000 after purchasing an additional 644,236 shares during the period. Maverick Capital Ltd. raised its position in Sotera Health by 3.5% during the 3rd quarter. Maverick Capital Ltd. now owns 3,497,367 shares of the company's stock worth $58,406,000 after purchasing an additional 118,353 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Sotera Health by 19.4% in the third quarter. Geode Capital Management LLC now owns 2,755,391 shares of the company's stock worth $46,026,000 after acquiring an additional 447,186 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Sotera Health by 45.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company's stock worth $22,308,000 after purchasing an additional 507,147 shares during the period. Institutional investors and hedge funds own 91.03% of the company's stock.

Remove Ads

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Barclays dropped their target price on shares of Sotera Health from $17.00 to $16.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. The Goldman Sachs Group assumed coverage on shares of Sotera Health in a report on Friday, December 6th. They set a "neutral" rating and a $14.00 price objective on the stock. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, Sotera Health currently has an average rating of "Moderate Buy" and an average target price of $16.00.

Sotera Health Stock Performance

NASDAQ SHC traded down $0.03 on Friday, hitting $11.77. 863,596 shares of the stock traded hands, compared to its average volume of 1,170,256. The firm has a market capitalization of $3.34 billion, a price-to-earnings ratio of 47.08 and a beta of 1.92. The business's fifty day moving average is $12.84 and its two-hundred day moving average is $14.00. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88. Sotera Health has a 12 month low of $10.71 and a 12 month high of $17.08.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.